TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02016924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Tablets administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR
Description: Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Solution administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Solution administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Solution administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Solution administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Third Unboosted Drug
Description: ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
Study: NCT02258659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given PO
Study: NCT02016924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Third Unboosted Drug
Description: ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Third Unboosted Drug
Description: ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS
Description: Tablets for oral suspension
Study: NCT02258659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03078569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: treatment with testosterone gel
Study: NCT03064945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Livia
Description: Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Livia
Description: Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
Study: NCT00158197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management voucher
Description: participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management voucher
Description: participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management voucher
Description: participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
Study: NCT03861091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Dose not applicable, given once 7-21 days prior to initiation of SBRT
Study: NCT02472158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chlorhexidine-gel-impregnated dressing
Description: Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
Study: NCT00863759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantation of intraocular lens (IOL)
Description: implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantation of intraocular lens (IOL)
Description: implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye.
Study: NCT01791998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance thermal imaging
Description: Undergo MR-thermal image guided LITT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser interstitial thermal therapy
Description: Undergo MR-thermal image guided LITT
Study: NCT04204382

Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin Injection
Description: Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Injection
Description: Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Kushen Injection（CKI）
Description: CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
Study: NCT01913457

Intervention type: RADIATION
Intervention: Ultrasound Doppler
Description: Doppler Ultrasound recording on external right chest wall

Intervention type: RADIATION
Intervention: Ultrasound Doppler
Description: Doppler Ultrasound recording on external right chest wall

Intervention type: RADIATION
Intervention: Ultrasound Doppler
Description: Doppler Ultrasound recording on external right chest wall
Study: NCT00214253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione
Description: Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
Study: NCT02797522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-521 Injection
Study: NCT02472158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethane film dressing
Description: Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
Study: NCT01664702

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy Products
Description: See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy Servings
Description: Continue baseline consumption of one or fewer servings of dairy per day
Study: NCT04380870

Intervention type: DIETARY_SUPPLEMENT
Intervention: Chinese Herbal Medicine
Description: Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
Study: NCT01449292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment plus Optimal Medical Therapy
Description: Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
Study: NCT00670722

Intervention type: DRUG
Intervention: insulin aspart
Description: Intervention at the discretion of the physician

Intervention type: DRUG
Intervention: insulin aspart
Description: Intervention at the discretion of the physician

Intervention type: DRUG
Intervention: insulin detemir
Description: Intervention at the discretion of the physician

Intervention type: DRUG
Intervention: insulin detemir
Description: Intervention at the discretion of the physician

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Intervention at the discretion of the physician
Study: NCT02144038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: pan-PIM inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: pan-PIM inhibitor
Study: NCT02144038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: pan-PIM inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: PI3K-alpha inhibitor
Study: NCT02797522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
Study: NCT02144038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: PI3K-alpha inhibitor
Study: NCT02797522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: Participants take entecavir OR tenofovir daily throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: Participants take entecavir OR tenofovir daily throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: Participants take entecavir OR tenofovir daily throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: Participants take entecavir OR tenofovir daily throughout the study.
Study: NCT06541769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limb hypothermia
Description: Limb hypothermia with special gel-gloves

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limb compression
Description: compression with sterile one way Latex gloves. Size measured for every Patient individually
Study: NCT01251770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45% NaCl/dextrose 5%
Description: Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% NaCl/dextrose 5%
Description: Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
Study: NCT02056626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Study: NCT00234702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02188680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAPS diet
Description: FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low FODMAPS diet
Description: FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
Study: NCT00725335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative resection without Pringle
Description: Radical excision of liver cancer without the procedure of pringle manoeuvre

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: curative resection with Pringle manoeuvre
Description: curative resection liver cancer under pringle manoeuvre
Study: NCT02015507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Study: NCT02511444

Intervention type: OTHER
Group type: OTHER
Intervention: GBS culture and real time PCR
Description: patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
Study: NCT03059277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Description: Intravitreal Aflibercept 2mg
Study: NCT02493452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04200638

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Description: The canal fluid sample before and after will evaluate after root canal instrumentation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Description: The canal fluid sample before and after will evaluate after root canal instrumentation
Study: NCT00843505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Smoking Cessation Program
Description: Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Quitline Smoking Cessation Program
Description: Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
Study: NCT02308397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal gluten containing bread
Description: Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced gliadins content
Description: Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced ATIs content
Description: Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with reduced overall protein content
Description: Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
Study: NCT01598077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Study: NCT04884919

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Regular Gauze
Description: Regular gauze

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan Dressing
Description: Dressing made of chitosan material
Study: NCT04611165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~* EBRT begins 2-7 days after the first dose of nivolumab.~* The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies.